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Background/Aims
Noncardiac chest pain (NCCP) is a very common disorder world-wide and gastroesophageal reflux disease (GERD) is known to 
be the most common cause. The prevalence of NCCP may tend to decrease with increasing age. However, there is little report 
about young aged NCCP. The aim of this study was to examine the prevalence of GERD and to evaluate the efficacy of proton 
pump inhibitor (PPI) test in the young NCCP patients. 
Methods
Thirty patients with at least weekly NCCP less than 40 years were enrolled. The baseline symptoms were assessed using a daily 
symptom diary for 14 days. Esophago-gastro-duodenoscopy (EGD) and 24 hr esophageal pH monitoring were performed for 
the diagnosis of GERD and esophageal manometry was done. Then, patients were tried with lansoprazole 30 mg twice daily 
for 14 days, considering positive if a symptom score improved ≥  50% compared to the baseline. 
Results
Nine (30%) of the patients were diagnosed with GERD at EGD and/or 24 hr esophageal pH monitoring, also, 3 (10%) were 
diagnosed with GERD-associated esophageal motility disorder and 3 (10%) were non GERD-associated. Concerning PPI test, 
GERD-related NCCP had a higher positive PPI test (n = 8, 89%) than non GERD-related NCCP (n = 5, 24%) (p = 0.002).
Conclusions
In young patients with NCCP, a prevalence of GERD diagnosed using EGD and/or 24 hr esophageal pH monitoring was 30%. 
PPI test was very predictable on diagnosis of GERD-related NCCP, thus, PPI test in young NCCP patients may assist to the 
physician’s clinical judgment of NCCP.
(J Neurogastroenterol Motil 2010;16:166-171)
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Introduction
Noncardiac chest pain (NCCP) is defined as recurring angi-
na-like or substernal chest pain believed to be unrelated to the 
heart after a reasonable cardiac evaluation,
1-3 and affects approx-
imately one-third of the population during their lifetime.
3,4 It is a 
benign condition with an estimated 10-year mortality of less than 
1%.
5 However, the associated morbidity, as a result of the inabil-
ity to work and the related health care utilization, are enormous.
6 
Gastroesophageal reflux disease (GERD) is known to be the 
most common cause of NCCP,
7-9 being in up to 60% of patients 
with NCCP.
10 The available diagnostic tests including esoph-
ago-gastro-duodenoscopy (EGD), esophageal manometry, 24 hr 
esophageal pH monitoring, esophageal pH-impedance monitor-
ing, and an empirical trial with a high-dose proton pump in-
hibitor (PPI) during a short course.
11-14 
Young age may be one of the potential risk factors for 
NCCP.
15 In clinical setting, we have experienced a number of 
young NCCP cases with the different clinical features. However, 
the majority of studies on NCCP have not focused on a specific 
age group. In fact, the importance of NCCP in young patients 
deserves careful attention considering its influence on their active 
social life and their low likelihood of cardiac abnormality.
16 
Therefore, there could be a renewal of interest in the in-
dividualised diagnosis and management for young adults. 
However, there has been little report of this aged NCCP.
The aim of this study was to examine the prevalence of 
GERD in the young patients with NCCP, and to evaluate the 
clinical characteristics and the usefulness of the empirical trial 
with PPI.
Materials and Methods
1. Patients
We performed a study for patients with NCCP less than 40 
years at the Konkuk University Medical Center, Seoul, Korea, 
from April 2007 to December 2008. The patients were visited to 
the coronary unit for at least one episode of unexplained chest 
pain per week, for a minimum 3 months. After visit to the coro-
nary unit, patients had a normal admission electrocardiogram, no 
abnormalities of cardiac enzymes, negative treadmill exercise 
testing, and/or normal or insignificant findings on coronary 
angiograms. And then, the eligible patients were referred to 
gastroenterology. Exclusion criteria included severe liver, lung, 
renal, or hematological disorders, a history of peptic ulcer disease 
or gastrointestinal surgery, a history of a connective tissue dis-
order, and chest pain originating from a musculoskeletal 
disorder. Patients were also excluded if they were already using 
antireflux medications such as PPI or H2 receptor blocker and 
pain modulators such as benzodiazepine, tricyclic antidepressant 
or selective serotonin reuptake inhibitor, or if they were unwilling 
or unable to provide informed consent, or if they could not com-
plete all phases of the study. Informed written consent was ob-
tained from all participating patients. This study was approved by 
the Institutional Review Board of Konkuk University Medical 
Center.
2. Study protocol
For the baseline assessment, the clinical and symptomatic 
characteristics were investigated by using a structured ques-
tionnaire and the upper gastrointestinal tests including EGD, 
esophageal manometry and ambulatory 24 hr esophageal pH 
monitoring were performed. All patients were classified as 
GERD-related NCCP or non GERD-related NCCP based on 
t h e  r e s u l t s  o f  E G D  a n d  a m b u l a t o r y  2 4  h r  e s o p h a g e a l  p H  
monitoring. Documentation of reflux esophagitis on EGD 
and/or pathologic acid exposure on ambulatory 24 hr esophageal 
pH monitoring was used to determine the presence of GERD. 
Also, the baseline symptom assessment was accomplished using a 
daily symptom diary for 14 days. Following the baseline assess-
ments, the patients were entered into the therapeutic trial of lan-
soprazole 30 mg am before breakfast and 30 mg pm before din-
ner for 14 days. During this period of the lansoprazole trial, the 
patients continued to keep the same daily symptom diary.
3. Upper gastrointestinal tests 
1) Esophago-gastro-duodenoscopy 
EGD was conducted by an experienced endoscopist with 
standard endoscopes (XQ-260, Olympus Optical Co. Ltd., 
Tokyo, Japan) after an overnight fast. The distal portion of the 
esophagus was carefully examined to determine the presence of 
mucosal injury. The extent of esophageal mucosal damage was 
assessed according to the Los Angeles classification.
17
2) Esophageal manometry
Esophageal manometry was undergone before pH-monitor-
ing studies according to current standard guidelines. Esophageal 
manometry was performed using a standard 4.5 mm diameter, 
water-perfused, 6-channel Esophageal manometry catheter Tae Ho Seo, et al
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Figure 1. Upper gastrointestinal evaluation. Gastroesophageal 
reflux disease (GERD)-related noncardiac chest pain (NCCP) was 
found in nine (30%) of 30 patients on EGD and/or ambulatory 24 hr 
esophageal pH monitoring and esophageal motility disorder was 
found in 6 patients (20%) including 5 with ineffective esophageal 
motility and 1 with nutcracker esophagus. Also, GERD-associated 
esophageal motility disorder was found in 3 (10%) and non 
GERD-associated esophageal motility disorder in only 3 patients 
(10%). Non GERD, non GERD-related NCCP; Nutcracker, 
nutcracker esophagus; IEM, ineffective esophageal motility. 
(Dentsleeve Oesophageal LES sleeve catheter, Medtronics, 
Minneapolis, MN, USA). The catheter was passed transnasally 
and positioned with the most distal channel in the stomach, the 
next most proximal (Dentsleeve, Medtronics, Minneapolis, 
MN, USA) in the lower esophageal sphincter (LES), and the re-
maining channels in the esophagus at 5, 10, 15 and 20 cm above 
LES. With the patient supine, five ‘wet’ swallows, each consist-
ing of 5 mL of water, were given at intervals of 20 seconds. 
Peristaltic activity and LES function were observed and if any 
abnormalities were detected a further five 5 mL ‘wet’ swallows 
were given (‘full’ manometric study). On completion of the swal-
lows, the catheter was slowly withdrawn, the upper esophageal 
sphincter position and function observed, and the catheter re-
moved, and a series of 15 wet swallows was performed. The diag-
nosis of each esophageal motility abnormality was verified, ac-
cording to the accepted published criteria.
18
3) Ambulatory 24 hr esophageal pH monitoring
Ambulatory 24 hr esophageal pH monitoring was conducted 
with a 2.1 mm diameter monocrystalline pH catheter equipped 
with 2 antimony electrodes (Synectics, Irving, TX, USA) sepa-
rated 15 cm apart off PPI for 7 days. The catheters were in-
troduced transnasally, in order to position the sensors 5 cm above 
the upper edge of the manometrically determined LES. The 
esophageal acid exposure values (percentage of the time the pH 
was ＜ 4.0) were calculated using a commercial software pro-
gram (EsoPHogram, version 5.70C2, Gastrosoft Inc., Irving, 
TX, USA). Pathologic acid exposure was defined as an intra-
esophageal pH of less than 4, for more than 4.0% of the record-
ing time.
19  
4. PPI test 
For 14 days, patients recorded the frequency and severity of 
chest pain daily using a daily symptom diary. The severity was ex-
pressed in the following 4 grades: mild (1, the symptom was easi-
ly tolerated and did not last long); moderate (2, the symptom 
caused some discomfort, but did not interfere with usual activ-
ities); severe (3, the symptom caused a great deal of discomfort, 
and interfered with usual activities); and disabling (4, the symp-
tom was unbearable and interfered considerably with usual activ-
ities).
7 A symptom intensity score was calculated by adding the 
reported daily severity multiplied by the reported daily frequency 
values obtained for 14 days at baseline, then for the same days of 
the lansoprazole trial. This test was considered positive if the 
symptom intensity score improved by more than 50% from the 
baseline.
11 
5. Statistical methods 
The Mann-Whitney U test was utilized to examine the dif-
ference in the baseline symptom scores between GERD-related 
NCCP and non GERD-related NCCP groups. A comparison of 
the PPI test results (positive or negative) between GERD-re-
lated NCCP and non GERD-related NCCP groups was accom-
plished utilizing the Fisher’s Exact Test. A p ＜ 0.05 was con-
sidered significant. 
Results
Forty consecutive patients with NCCP less than 40 years 
were screened. Among them, 2 had a history of peptic ulcer dis-
ease, 2 had a history of a connective tissue disorder, and 6 de-
clined ambulatory 24 hr esophageal pH monitoring or had tech-
nically unsuccessful monitoring. As result, 30 patients were en-
rolled in this study (17 men and 13 women with a mean age of 
32.2 ± 5.8 years). 
The patients were classified into 2 groups, GERD-related 
NCCP and non GERD-related NCCP according to the results Noncardiac Chest Pain in Young Patients 
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Table 1. Patients’ Characteristics
GERD-related Non  GERD-related 
                                                                 p-value
NCCP (n = 9) NCCP (n = 21)
Age [mean yr ± SD]   33.5 ± 6.5 31.5 ± 5.2 0.57
Sex [M/F]          5/4       12/9 0.35
BMI [kg/m
2, mean ± SD]   22.8 ± 1.1 23.8 ± 2.1 0.46
Smoking [n (%)]      5 (42%)     7 (33%) 0.45
Alcohol [n (%)]      5 (42%)     8 (38%) 0.65
Daily symptom intensity [mean ± SD]   4.61 ± 4.10 4.54 ± 3.75 0.91
Symptom frequency [n (%)] ≥ 1/day       3 (33%)     7 (33%) 0.56
3/wk ≤   ＜ 1/day      3 (33%)     9 (43%)
1/wk ≤   < 3/wk      3 (33%)     5 (24%)
Symptom duration [n (%)] 3 mo-6 mo      2 (12%)     3 (14%) 0.32
6 mo-1 yr      1 (11%)     3 (14%)
1 yr-5 yr      4 (45%)   13 (62%)
> 5 yr      2 (12%)     2 (10%)
Reflux esophagitis [n (%)]      8 (89%)     0 (0%)
LA grade A      6 (67%)
LA grade B      1 (11%)
LA grade C      1 (11%)
LA grade D      0 (0%)
Pathologic acid exposure [n (%)]
a      6 (67%)     0 (0%)
Esophageal pH [mean percentage ± SD]
% total time pH ＜ 4 10.23 ± 11.05 1.55 ± 1.23 0.02
% upright time pH ＜ 4 14.53 ± 13.25 2.35 ± 2.28 0.01
% supine time pH ＜ 4   2.58 ± 9.22 0.34 ± 0.19 0.04
aPathologic acid exposure, percentage of the time for intraesophageal pH ＜ 4 more than 4.0%.
GERD, gastroesophageal reflux disease; NCCP, noncardiac chest pain; BMI, body mass index; LA, Los Angeles classification; NS, not significant.
Bold style indicates statistical significance.
Figure 2. A comparison of proton pump inhibitor (PPI) testing 
between gastroesophageal reflux disease (GERD)-related 
noncardiac chest pain (NCCP) and non GERD-related NCCP 
groups. During the 14 days of the PPI trial, the percent of positive 
PPI tests was significantly higher in GERD-related NCCP group 
(89%) compared to non GERD-related NCCP group (29%). p =
0.002.
of EGD and/or ambulatory 24 hr esophageal pH monitoring. 
GERD-related NCCP group included nine patients (30%). 
Reflux esophagitis was found in seven patients on EGD and 
pathologic acid exposure was identified in 6 patients on ambula-
tory 24 hr esophageal pH monitoring. Four patients had both re-
flux esophagitis and pathologic acid exposure. Non GERD-re-
lated NCCP group, with 21 patients (70%), had both normal 
EGD and pH test results. On esophageal manometric examina-
tion, esophageal motility disorder was found in 6 patients (20%). 
Five of 6 patients had ineffective esophageal motility (IEM) and 
1 had nutcracker esophagus. Three of the 5 IEM patients also 
had GERD (GERD-associated esophageal motility disorder) 
and the other 3 patients did not have GERD (non GERD-asso-
ciated esophageal motility disorder) (Fig. 1). 
GERD-related NCCP and non GERD-related NCCP 
groups did not differ significantly in age, gender, mean body 
mass index (BMI, kg/m
2), smoking history, or history of chronic 
alcoholism. The baseline symptom intensity score for chest pain 
showed no significant difference between GERD-related NCCP Tae Ho Seo, et al
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and non GERD-related NCCP groups. The 2 groups also did 
not differ significantly in the duration or frequency of symptoms 
(Table 1). 
During the 14 days of the PPI trial, 8 patients (89%) had a 
positive PPI test (＞ 50% symptom improvement) in GERD-re-
lated NCCP group and 6 patients (29%) had a positive PPI test 
in non GERD-related NCCP group. This difference was stat-
istically significant (p = 0.002) (Fig. 2). 
Discussion
In this present study, we examined the prevalence of GERD 
in the patients with NCCP less than 40 years, and to evaluate the 
usefulness of the empirical trial with PPI. In this uncontrolled 
trial, 9 (30%) of the patients with NCCP were diagnosed with 
GERD at EGD and/or 24 hr esophageal pH monitoring. Also, 
we found that the 2 weeks PPI trial resulted in symptom im-
provement in 89% of GERD-related NCCP patients and this re-
sult was statistically significant compared with non GERD-re-
lated NCCP patients. 
NCCP is a very common disorder world-wide, presenting in 
approximately 23-33% of the population.
20,21 Several pathophy-
siological mechanisms have been suggested including GERD, 
esophageal motility disorders, visceral hyperalgesia, psychiatric 
disturbances, abnormal cerebral processing of visceral stim-
ulation, and disrupted autonomic activity.
22,23 The diagnosis and 
management of patients with NCCP is a frequent and perplexing 
problem facing clinicians. Most patients continue to present a di-
agnostic and therapeutic challenge to their primary care physi-
cians after a reasonable cardiac evaluation. These patients are fre-
quently highly debilitated and tend to use a disproportionate level 
of health care resources, including recurrent doctor and emer-
gency room visits, hospitalizations, and prescription medications, 
leading them to indicate poor satisfaction with their medical 
care.
24 
Concerning age factors, the recent report by Eslick et al.
3 
showed that the prevalence of NCCP tended to decrease with in-
creasing age in the population-based study. Moreover, young age 
may be one of the potential risk factors for NCCP.
15 In clinical 
setting, we have experienced a number of young NCCP cases 
with some different characteristics comparing with average aged 
NCCP. However, there has been little report about the patho-
physiological mechanisms, diagnosis, and management of young 
aged NCCP. In this present study, we focused on the prevalence 
of GERD and the diagnostic value of PPI test of the young aged 
NCCP patients, exclusively. In NCCP patients less than 40 
years, the proportion of GERD-related NCCP diagnosed from 
EGD and/or 24 hr esophageal pH monitoring was 30%. 
Recently, using this same design in the same geography and eth-
nicities, we reported that the proportion of GERD-related 
NCCP diagnosed from EGD and/or 24 hr esophageal pH mon-
itoring in the average aged subjects was 41%.
7 Comparing with 
this previous data, our present ratio, interestingly, tends to be low. 
This suggests that there may be more possibilities of other patho-
physiological mechanisms except GERD in the young aged 
NCCP, for example, visceral hyperalgesia, psychiatric dis-
turbances, and so on. Recent studies of the biomechanical proper-
ties of the esophagus and esophageal sensation demonstrated that 
aging was associated with a larger lumen and a stiffer but less sen-
sitive esophageal wall, and a lower threshold for pain and dis-
comfort was noticed in young patients.
16 
The relationship to esophageal symptoms for motility abnor-
malities may be even more problematic. These are reflected by the 
American Gastroenterological Association guidelines on esoph-
ageal manometry, which recommended that it should not be used 
as the initial test for the evaluation of patients with NCCP.
25 In 
our study, non GERD-associated esophageal motility disorders 
were found in only 10%. 
Also, we examined the effect of PPI testing, in patients with 
weekly NCCP or more than weekly. Several observations have 
confirmed the usefulness of PPI therapy for the diagnosis of 
NCCP.
11,12,14 The PPI test is a simple, non-invasive diagnostic 
tool for GERD. It is readily available at the disposal of primary 
care physicians and increases their role in evaluating and treating 
patients with the spectrum of GERD. It offers significant cost 
savings when compared to other diagnostic tests. In our previous 
data, that is 81% of positive PPI test for the GERD in NCCP 
patients, it has been demonstrated that 2 weeks of high-dose PPI 
is a simple and clinically practical method for diagnosing GERD 
in Korea, as well.
14 While, in the present trial, the lansoprazole 
trial resulted in symptom improvement in 89% of GERD-related 
NCCP patients and this result was statistically significant com-
pared with non GERD-related NCCP patients. Comparing with 
our previous data, this ratio tends to be similar or rather high. 
This result suggests that an empirical trial with a high-dose PPI 
is a simple and accurate method for diagnosing GERD-related 
NCCP in young patients with NCCP, as well.
Our present study has several important limitations. This 
study design did not include the average aged patients with 
NCCP and a placebo control for PPI test. However, there are Noncardiac Chest Pain in Young Patients 
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some important and consistent findings, comparing with our pre-
vious average aged subject studies for NCCP with the same ge-
ography and ethnicities and the similar sample size and frame. In 
young aged NCCP patients, the proportion of GERD-related 
NCCP tended to be less frequent, in spite of no comparative 
analysis of the average aged NCCP patients. An empirical trial 
with a high-dose PPI during 2 weeks was highly diagnostic for 
patients with GERD-related NCCP in young aged NCCP pa-
tients, therefore, PPI test may assist either directly or supple-
mentary to the physician’s clinical judgment of young aged 
NCCP, preferably. 
To accurately comprehend the differences of the prevalence 
of GERD according to age in patients with NCCP, their system-
ized symptomatic characteristics, and the clinical usefulness of 
the empirical trial with PPI, a large-scale investigation with 
case-control comparative design for young aged and average aged 
NCCP patients should be considered in the near future.  
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